Eone Diagnomics Genome Center Co., Ltd. (245620) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Eone Diagnomics Genome Center Co., Ltd. (245620:KRX), powered by AI.

Current Price
₩415
P/E Ratio
5.3
Market Cap
150.7B
Sector
Healthcare
What is the Eone Diagnomics Genome Center Co., Ltd. stock price forecast?

Eone Diagnomics Genome Center Co., Ltd. is currently trading at ₩415. View real-time AI analysis on Alpha Lenz.

What is Eone Diagnomics Genome Center Co., Ltd. insider trading activity?

View the latest insider trading data for Eone Diagnomics Genome Center Co., Ltd. on Alpha Lenz.

What is Eone Diagnomics Genome Center Co., Ltd.'s P/E ratio?

Eone Diagnomics Genome Center Co., Ltd.'s P/E ratio is 5.3.

Eone Diagnomics Genome Center Co., Ltd.

KRX · 245620
₩415+0(+0.00%)Market closedKRX regular session 09:00–15:30 KST
Ask about Eone Diagnomics Genome Center Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Eone Diagnomics Genome Center Co., Ltd. trades at a P/E of 5.3 (undervalued) with modest ROE of -297.1%.

Ask for details

Company Overview

Eone Diagnomics Genome Center Co., Ltd. is a biotechnology company specializing in the genomic analysis field. Its primary focus is on providing advanced genomic services and developing innovative diagnostic solutions, leveraging cutting-edge technologies in genetic sequencing and personalized medicine. The company is instrumental in impacting healthcare and research sectors by offering comprehensive genomic data analyses that aid in the early detection, treatment, and management of diseases. Eone Diagnomics Genome Center serves a diverse clientele, including hospitals, research institutions, and pharmaceutical companies, facilitating more precise and customized medical interventions. With the growing emphasis on precision medicine, the company plays a significant role in enhancing healthcare outcomes through its state-of-the-art genomic solutions. By continually expanding its capabilities and collaborations, Eone Diagnomics Genome Center contributes to advancing the understanding of the human genome and its application to improve health.

CEO대표이사 이민섭
SectorHealthcare
IndustryMedical Distribution
Employees103

Company Statistics

FY 2025

Profile

₩150,735,648,852Market Cap
₩7,886,099,040Revenue
60.55MShares Out
103Employees

Margins

38.95%Gross
418.23%EBITDA
-20.25%Operating
358.49%Pre-Tax
358.13%Net

Valuation

5.34P/E
-6.69P/B
19.11EV/Sales
5.17EV/EBITDA
43.47P/FCF

Growth (CAGR)

-56.26%Rev 3Yr
-38.89%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

31.57%ROA
-297.12%ROE
36.11%ROIC

Financial Health

₩13,392,104,510Cash & Cash Equivalents
₩53,146,776,110Net Debt
-295.39%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Eone Diagnomics Genome Center Co., Ltd. (ticker: 245620) is a company listed on KRX in the Healthcare sector (Medical Distribution). It has approximately 103 employees. Market cap is $150.7B.

The current price is ₩415 with a P/E ratio of 5.34x and P/B of -6.69x.

ROE is -297.12% and operating margin is -20.25%. Annual revenue is $7.9B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Eone Diagnomics Genome Center Co., Ltd. (Healthcare) Stock Forecast & Analysis ₩415 | Alpha Lenz